CAJ | 학술논문

目的探讨帕利哌酮缓释片改善精神分裂症患者症状和社会功能的效果.方法将81例精神分裂症患者随机分为研究组(41例,帕利哌酮缓释片系统治疗)和对照组(40例,利培酮系统治疗),共治疗12周,基线时、治疗后第6周末及治疗后第12周末应用阳性与阴性症状量表(PANSS)、社会功能缺陷量表(SDSS)和副反应量表(TESS)分别进行评定.结果研究组在治疗第12周末的PANSS各因子分及总分[(12.0±2.8)分、(12.1±3.6)分、(26.2±5.0)分、(50.2±8.7)分]均低于基线评分[(24.7±5.3)分、(23.8±3.6)分、(45.0±2.9)分、(93.5±6.8)分],差异均具有统计学意义(t=9.60～16.78,P＜0.05).研究组在治疗第12周末的PANSS阳性症状、阴性症状因子分及总分[(12.0±2.8)分、(12.1±3.6)分、(50.2±8.7)分]均低于第6周末评分[(14.2±1.8)分、(14.6±2.4)分、(56.5±6.4)分],差异均具有统计学意义(t=2.58～4.26,P＜0.05).在治疗第12周末,研究组的PANSS各因子分及总分[(12.0±2.8)分、(12.1±3.6)分、(26.2±5.0)分、(50.2±8.7)分]均低于对照组评分[(16.9±4.9)分、(18.7±5.3)分、(32.5±5.1)分、(68.1±13.0)分],差异具有统计学意义(t=-4.28～-5.67,P＜0.05).研究组在治疗第12周末的SDSS总分[(5.9±2.8)分]低于基线评分[(13.9±3.4)分],差异具有统计学意义(t=10.83,P＜0.05).研究组在治疗第12周末的SDSS总分[(5.9±2.8)分]低于第6周末评分[(7.6±2.9)分],差异均具有统计学意义(t=5.21,P＜0.05),而对照组无显著性变化(t=1.88,P＞0.05).在治疗第12周末,研究组的SDSS总分[(5.9±2.8)分]低于对照组评分[(8.8±2.9)分],差异具有统计学意义(t=-4.49,P＜0.05).研究组的不良反应与对照组相当,均未见严重不良反应.结论帕利哌酮缓释片可有效改善精神分裂症患者的社会功能以及精神症状.
목적 탐토파리고동완석편개선정신분렬증환자증상화사회공능적효과.방법 장81례정신분렬증환자수궤분위연구조(41례,파리고동완석편계통치료)화대조조(40례,리배동계통치료),공치료12주,기선시、치료후제6주말급치료후제12주말응용양성여음성증상량표(PANSS)、사회공능결함량표(SDSS)화부반응량표(TESS)분별진행평정.결과 연구조재치료제12주말적PANSS각인자분급총분[(12.0±2.8)분、(12.1±3.6)분、(26.2±5.0)분、(50.2±8.7)분]균저우기선평분[(24.7±5.3)분、(23.8±3.6)분、(45.0±2.9)분、(93.5±6.8)분],차이균구유통계학의의(t=9.60～16.78,P＜0.05).연구조재치료제12주말적PANSS양성증상、음성증상인자분급총분[(12.0±2.8)분、(12.1±3.6)분、(50.2±8.7)분]균저우제6주말평분[(14.2±1.8)분、(14.6±2.4)분、(56.5±6.4)분],차이균구유통계학의의(t=2.58～4.26,P＜0.05).재치료제12주말,연구조적PANSS각인자분급총분[(12.0±2.8)분、(12.1±3.6)분、(26.2±5.0)분、(50.2±8.7)분]균저우대조조평분[(16.9±4.9)분、(18.7±5.3)분、(32.5±5.1)분、(68.1±13.0)분],차이구유통계학의의(t=-4.28～-5.67,P＜0.05).연구조재치료제12주말적SDSS총분[(5.9±2.8)분]저우기선평분[(13.9±3.4)분],차이구유통계학의의(t=10.83,P＜0.05).연구조재치료제12주말적SDSS총분[(5.9±2.8)분]저우제6주말평분[(7.6±2.9)분],차이균구유통계학의의(t=5.21,P＜0.05),이대조조무현저성변화(t=1.88,P＞0.05).재치료제12주말,연구조적SDSS총분[(5.9±2.8)분]저우대조조평분[(8.8±2.9)분],차이구유통계학의의(t=-4.49,P＜0.05).연구조적불량반응여대조조상당,균미견엄중불량반응.결론 파리고동완석편가유효개선정신분렬증환자적사회공능이급정신증상.
Objective To explore the efficacy of paliperidone extended-release tablets in the improvement of social functions in schizophrenics. Methods A total of 81 schizophrenics were randomly divided into study group with paliperidone extended-release tablets and control group with risperidone for a 12-week treatment. They were assessed and analyzed by positive and negative symptoms scales( PANSS),social disability screening schedule (SDSS)and treatment emergent symptom scale (TESS)at baseline, 6th weekend and 12th weekend. Results In study group, the factors and total scores of PANSS in the 12th weekend of treatment [( 12. 0 ± 2. 8), ( 12. 1 ± 3. 6), ( 26. 2 ± 5.0), (50. 2 ± 8.7 )] were all significantly lower than those at baseline [(24.7 ±5.3), (23.8 ±3.6), (45.0 ±2.9), (93.5 ±6.8)] (t =9.60-16. 78, P＜0. 05). In study group, the positive factor, negative factor and total scores of PANSS in the 12th weekend of treatment [( 12. 0 ± 2. 8), ( 12. 1 ± 3.6), (50. 2 ± 8. 7 )] were all significantly lower than those in the 6th weekend of treatment [(14.2 ±1.8),(14.6 ±2.4),(56.5 ±6.4)] (t =2.58-4. 26, P＜0.05).In the 12th weekend of treatment, the factors and total scores of PANSS in study group [( 12. 0 ± 2. 8),( 12. 1 ± 3.6 ), ( 26. 2 ± 5.0 ), ( 50. 2 ± 8.7 )] were all significantly lower than those in control group [(16.9 ±4.9), (18.7±5.3), (32.5 ±5.1), (68. 1 ±13.0)](t= -4.28-5.67,P＜0.05). In study group, the total scores of SDSS in the 12th weekend of treatment(5.93 ±2. 78) were significantly lower than those at baseline ( 13. 9 ± 3.4) ( t = 10. 83, P ＜ 0. 05 ). In study group, the total scores of SDSS in the 12th weekend of treatment (5.9 ± 2. 8 )were significantly lower than those in the 6th weekend of treatment (7.6 ±2. 9) (t =5.21, P ＜0. 05). But there was no significant improvement in control group(t = 1.88, P ＞0. 05).In the 12th weekend of treatment, the total scores of SDSS in study group (5.9 ± 2. 8) were significantly lower than those in control group(8. 8 ± 2. 9 ) ( t = - 4. 49, P ＜ 0. 05 ). No severe adverse effect was reported in either group. Conclusion Paliperidone extended-release tablets are effective to improve social functions and psychiatric symptoms of schizophrenics.